PetVivo's 2025 Q3 Earnings Call: Funding Challenges, Market Focus, and Strategic Shifts Unveiled

These are the key contradictions discussed in PetVivo's latest 2025 Q3 earnings call, specifically including: Fundraising Efforts, Market Focus and Future Human Studies, and Company Growth Strategy:



Revenue and Distribution Growth:
- PetVivo reported a 191% sequential increase in revenues to $583,000, with the nationwide distributor network contributing $545,000.
- The growth was driven by the expansion of the distribution network for its lead animal osteoarthritis medical device, Spryng, and a strategic focus on the companion animal market.

Cost Reduction and Efficiency:
- The company's operating expenses for the 9 months ending December 31, '24 decreased by $2 million (23%), with general and administrative expenses down $1 million and sales and marketing expenses down $1.2 million.
- This reduction was due to a strategic company-wide cost reduction and restructuring program, improving cost efficiency and cash management.

New Partnership and Product Launch:
- PetVivo announced a partnership with VetStem for Precise PRP, an innovative off-the-shelf platelet-rich plasma product for veterinary use.
- The partnership aligns with PetVivo's strategy to expand its product portfolio and enhance its offerings in the animal health market.